Knight Therapeutics Inc. (TSX: GUD) announced that it has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, demonstrating the company's financial strength and operational efficiency.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions, supporting the company's ongoing growth strategy across its pan-American pharmaceutical business. This repayment reduces debt and frees up capacity for future strategic initiatives, including potential acquisitions or investments in its pipeline.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD.
The repayment of the facility ahead of schedule signals Knight's ability to generate robust cash flows and manage its capital structure prudently. For investors, this move reduces interest expense and credit risk, potentially enhancing shareholder value. The maintained access to up to US$200 million in borrowing capacity provides flexibility to pursue growth opportunities without immediate financing constraints.
This development underscores the success of the Paladin acquisition strategy and Knight's operational discipline. The company's focus on specialty pharmaceuticals in niche markets continues to yield positive financial results.
